Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 63.74% is 14% above its 5-year average of 55.68%, near the high end of its 5-year range (42.27%–66.01%).
0.30% above its 12-month average of 63.55%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 66.01%.
GROSS MARGIN
63.74%
GROSS MARGIN AVG TTM
63.55%
GROSS MARGIN AVG 3Y
60.17%
GROSS MARGIN AVG 5Y
55.68%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.30%
CURRENT VS 3Y AVG
+5.93%
CURRENT VS 5Y AVG
+14.47%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+54.04%
vs the sector median at left
PROCEPT BioRobotics Corporation
Market Cap
$988.10M
Gross Margin
63.74%
TTM Avg
63.55%
3Y Avg
60.17%
5Y Avg
55.68%
Market Cap
$981.32M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$978.27M
Gross Margin
97.19%
TTM Avg
61.28%
3Y Avg
80.64%
5Y Avg
87.09%
Market Cap
$1.00B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
16.67%
Market Cap
$970.39M
Gross Margin
79.21%
TTM Avg
77.54%
3Y Avg
74.46%
5Y Avg
74.10%
Market Cap
$1.02B
Gross Margin
11.80%
TTM Avg
10.80%
3Y Avg
10.72%
5Y Avg
10.72%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PROCEPT BioRobotics Corporation (PRCT) | $988.10M | 63.74% | 63.55% | 60.17% | 55.68% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $986.21M | N/A | N/A | N/A | N/A |
| Vor Biopharma Inc. (VOR)vs › | $994.74M | 0.00% | 0.00% | 0.00% | 0.00% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $981.32M | 0.00% | 0.00% | 0.00% | 0.00% |
| MeiraGTx Holdings plc (MGTX)vs › | $978.27M | 97.19% | 61.28% | 80.64% | 87.09% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.00B | 0.00% | 0.00% | 0.00% | 16.67% |
| Pacira BioSciences, Inc. (PCRX)vs › | $970.39M | 79.21% | 77.54% | 74.46% | 74.10% |
| Immatics N.V. (IMTX)vs › | $1.01B | 100.00% | 100.00% | 100.00% | 64.23% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 11.80% | 10.80% | 10.72% | 10.72% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | 79.71% | 80.13% | 81.57% | -49.18% |
Gross Margin
63.7%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 66.01% |
| 2026-03-31 | 64.89% |
| 2025-12-31 | 60.63% |
| 2025-09-30 | 62.87% |
| 2025-06-30 | 63.35% |
| 2025-03-31 | 63.85% |
| 2024-12-31 | 64.00% |
| 2024-09-30 | 63.24% |
| 2024-06-30 | 59.01% |
| 2024-03-31 | 56.21% |
| 2023-12-31 | 48.77% |
| 2023-09-30 | 53.77% |
| 2023-06-30 | 55.67% |
| 2023-03-31 | 51.18% |
| 2022-12-31 | 44.90% |
| 2022-09-30 | 50.28% |
| 2022-06-30 | 50.84% |
| 2022-03-31 | 54.18% |
| 2021-12-31 | 44.55% |
| 2021-09-30 | 48.92% |
| 2021-06-30 | 42.27% |
| 2021-03-31 | 49.04% |
| 2020-12-31 | 14.59% |
| 2020-09-30 | -1.47% |
| 2020-06-30 | -70.87% |
| 2020-03-31 | -70.87% |
